Shares of Panacea Biotech were locked in the 10 per cent upper circuit for the second one straight day, at Rs 323.70, hitting an over 12-year high on the BSE on Thursday. The inventory of the biotechnology company was once trading at its highest level since August 2008. It had hit a record high of Rs 487 on April 21, 2006.
Thus far in the month of April, the market price of Panacea Biotech has zoomed 83 per cent after the company and the Russian Direct Investment Fund (RDIF) agreed to produce 100 million doses of Sputnik V vaccine in India per year. In comparison, the S&P BSE Sensex has slipped 4.4 per cent so far in the current month.
“The Russian Direct Investment Fund (RDIF), and Panacea Biotec announced cooperation to produce 100 million doses per year of Sputnik V, the world’s first registered vaccine against coronavirus,” the company said in a press release on April 4.
Production of Sputnik V at Panacea Biotec sites will help facilitate global provide of Sputnik V to international partners of RDIF. To date, Sputnik V has been registered in 59 countries globally with a complete population of over 1.5 billion people. The efficacy of Sputnik V is at 91.6 per cent as confirmed by the data published in the Lancet, one of the crucial world’s oldest and most respected medical journals.
“The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a class lesson of vaccination, providing immunity with a longer duration than vaccines the use of the same delivery mechanism for both shots,” it said.
Panacea Biotec is an innovation driven Biotechnology company doing research and development, manufacturing, sales, distribution and marketing of pharmaceuticals, vaccines and biosimilars. The company has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management diabetes management renal-disease management anti-osteoporosis anti-tubercular gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations.
Serum Institute of India Private Limited, the world’s largest vaccine manufacturer by number of doses produced and sold globally, held 4.98 per cent stake in Panacea Biotech.
Commerce Standard has all the time strived tough to supply up-to-date information and remark on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and fixed feedback on how to reinforce our offering have only made our get to the bottom of and commitment to these ideals stronger. Even right through these difficult times arising out of Covid-19, we continue to remain dedicated to keeping you informed and up to date with credible news, authoritative views and incisive remark on topical issues of relevance.
We, then again, have a request.
As we battle the economic affect of the pandemic, we need your give a boost to even more, in order that we will be able to continue to give you more quality satisfied. Our subscription mannequin has seen an encouraging response from many of you, who have subscribed to our online satisfied. More subscription to our online satisfied can only help us achieve the goals of offering you even better and more applicable satisfied. We consider in free, reasonable and credible journalism. Your give a boost to through more subscriptions can help us practise the journalism to which we are dedicated.
Improve quality journalism and subscribe to Commerce Standard.